Source: Annual Congress 2007 - Community-acquired pneumonia: from aetiology to complication
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
M. Martin, L. Moore, S. Quilici, T. File, J. Garau, M. Kubin, T. Evers (Uxbridge, Middlesex, United Kingdom; Akron, OH, United States Of America; Terrassa, Barcelona, Spain; Wuppertal, Germany). The impact of antimicrobial resistance on the cost-effectiveness of empirical treatment of community-acquired pneumonia (CAP) in France (FR), Belgium (BE) and Germany (DE). Eur Respir J 2007; 30: Suppl. 51, 3938

Member's Comments

No comment yet.

Related content which might interest you: Hospitalisation costs for community-acquired pneumonia (CAP) in France (F), Germany (D), Japan (J) and USA Source: Eur Respir J 2004; 24: Suppl. 48, 8s Year: 2004 Lower overall healthcare costs with telithromycin (TEL) versus clarithromycin (CLA) in community-acquired pneumonia (CAP) Source: Eur Respir J 2003; 22: Suppl. 45, 152s Year: 2003 The efficiency of moxifloxacin (MOX) in community-acquired pneumonias (CAP) treatment while the initial antibacterial therapy (IAT) was inefficient Source: Eur Respir J 2005; 26: Suppl. 49, 638s Year: 2005 Change in the susceptibility pattern of Streptococcus pneumoniae (SP) and risk factors (RF) for antibiotic resistance (AR) in patients with community-acquired pneumonia (CAP) Source: Eur Respir J 2003; 22: Suppl. 45, 546s Year: 2003 Optimizing treatment for community-acquired pneumonia in Denmark (The optiCAP study) Source: International Congress 2018 – Pneumonia: from the community to the intensive care unit Year: 2018 The analysis of efficiency of amoxycillin/clavulanate (AC) usage at inpatients with community-acquired pneumonia (CAP) Source: Eur Respir J 2006; 28: Suppl. 50, 2s Year: 2006 Relevance of correct antibiotic choice in community-acquired pneumonia (CAP) Source: Annual Congress 2005 - Community-acquired pneumonia: clinical approaches Year: 2005 Earlier discharge of patients treated with moxifloxacin IV/PO monotherapy (MXF) versus amoxicillin/clavulanate (AMC) ±] clarithromycin (CLA) for community-acquired pneumonia (CAP) results in cost savings to the German and French healthcare Source: Eur Respir J 2002; 20: Suppl. 38, 561s Year: 2002 Use of pneumonia severity index in Spain to decide hospitalization among patients with community-acquired pneumonia (CAP). (Nacar Study) Source: Eur Respir J 2005; 26: Suppl. 49, 637s Year: 2005 Surfactant protein D (SPD) like marker of effectiveness ofphosphatidylcholine treatment outcomes in patients (pts) with community acquired pneumonia (CAP) Source: International Congress 2015 – Healthcare organisation and appropriateness in lung disorders Year: 2015 Impact of age and gender on efficacy and safety of omadacycline (OMC) vs. moxifloxacin (MOX) in community-acquired bacterial pneumonia (CABP) Source: International Congress 2018 – New therapies for respiratory infections: experimental and translational studies Year: 2018 Efficacy of combined therapy in severe community-acquired pneumonia (CAP) with efferent detoxication methods (EDM) vs. standard therapy by antibiotics (STA) Source: Eur Respir J 2005; 26: Suppl. 49, 638s Year: 2005 Could procalcitonin (PCT) be a marker of effectiveness of antibiotic treatment (ABT) in pregnant with not severe community-acquired pneumonia (CAP)? Source: International Congress 2015 – Healthcare organisation and appropriateness in lung disorders Year: 2015 Definition of severity and the reasons for hospitalization (RH) in patients with community-acquired pneumonia (CAP) Source: Eur Respir J 2005; 26: Suppl. 49, 641s Year: 2005 I-ROAD could be efficient in predicting severity of community acquired pneumonia (CAP) or healthcare-associated-pneumonia(HCAP) Source: Annual Congress 2010 - Healthcare-associated pneumonia: ventilator-associated pneumonia and pneumonia in hospitalised patients Year: 2010 Determination of community acquired pneumonia (CAP) severity in pregnant (pr.) Source: Virtual Congress 2021 – Clinical features and challenges of COVID-19 Year: 2021 Effectiveness of the empirical administration of antibiotics in community acquired pneumonia (CAP) Source: Annual Congress 2007 - Antibiotic treatment in community-acquired pneumonia Year: 2007 Progress of quality indicator rates regarding treatment of patients hospitalized in Germany due to community acquired pneumonia (CAP) Source: Annual Congress 2010 - The spectrum of lower respiratory tract infections: risk factors of poor outcome and diagnostic tools Year: 2010 The use of phon resonant therapy (PRT) in treatment of patients with pulmonary tuberculosis, combined with infections, caused by chlamydia (C) and mycoplasma (M) Source: Eur Respir J 2004; 24: Suppl. 48, 52s Year: 2004 Macrolides vs quinolones in Legionella pneumonia treatment: CAPAVANT group. Valencia (Spain) Source: Annual Congress 2012 - Anti-infective treatment and resistance in respiratory infections Year: 2012